Spots Global Cancer Trial Database for folfox
Every month we try and update this database with for folfox cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | NCT00613080 | Colorectal Canc... | capecitabine oxaliplatin resection radiation thera... FOLFOX | 18 Years - | Radiation Therapy Oncology Group | |
| Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma | NCT05535647 | Intrahepatic Ch... | Regorafenib and... FOLFOX | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | NCT04488159 | Colon Cancer St... | Capecitabine Oxaliplatin Fluorouracil Leucovorin Immunoscore® as... Physical exerci... | 18 Years - 100 Years | Medical University of Vienna | |
| Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | NCT04488159 | Colon Cancer St... | Capecitabine Oxaliplatin Fluorouracil Leucovorin Immunoscore® as... Physical exerci... | 18 Years - 100 Years | Medical University of Vienna | |
| Neo-Adjuvant FOLFOX for Rectal Carcinoma | NCT00832299 | Rectal Neoplasm... | FOLFOX total mesorecta... | 18 Years - 70 Years | Beth Israel Medical Center | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer | NCT00994864 | Colon Cancer | FOLFOX | 18 Years - | Jules Bordet Institute | |
| BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer | NCT03838406 | BRCA Gene Rearr... | BRCA 1 Chemotherapy | 19 Years - | Chung-Ang University | |
| NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | NCT02486601 | Cancer of Stoma... | nab-paclitaxel FOLFOX | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells | NCT01640405 | Metastatic Colo... | modified FOLFOX... FOLFOXIRI + Bev... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma | NCT03528876 | Metastatic Gast... | FOLFOX and FOLF... | 18 Years - | University of Saskatchewan | |
| FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer | NCT00724503 | Colorectal Canc... Colorectal Carc... Liver Metastase... | SIR-Spheres ytt... Systemic chemot... | 18 Years - | Sirtex Medical | |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | NCT03117972 | Metastatic Colo... | FOLFOXIRI FOLFOX FOLFIRI Bevacizumab LV5FU2 Capecitabine | 18 Years - 76 Years | Centre Hospitalier Universitaire de Besancon | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery | NCT00265811 | Colorectal Canc... | Folfox Cetuximab | 18 Years - 74 Years | Federation Francophone de Cancerologie Digestive | |
| Sorafenib + mFOLFOX for Hepatocellular Carcinoma | NCT01775501 | Hepatocellular ... | Leucovorin Fluorouracil Oxaliplatin Sorafenib | 18 Years - | Massachusetts General Hospital | |
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | NCT01508000 | Colorectal Canc... Liver Metastase... KRAS Wild Type ... | FOLFOX6 Bevacizumab Panitumumab Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | NCT03202758 | Colorectal Canc... | Durvalumab, Tre... | 18 Years - | Centre Georges Francois Leclerc | |
| Phase 2 Study of DKN-01 in Colorectal Cancer | NCT05480306 | Colorectal Canc... Colorectal Aden... Colo-rectal Can... Colorectal Canc... | DKN-01 FOLFIRI Bevacizumab FOLFOX | 18 Years - | Leap Therapeutics, Inc. | |
| POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC | NCT02845908 | Malignant Neopl... | POF FOLFOX FOLFOX plus PAC... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer | NCT00116506 | Colorectal Canc... Neoplasm Metast... | erlotinib FOLFOX bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer | NCT02849106 | Colorectal Canc... | biopsy to obtai... | 18 Years - | Institut Curie | |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy | NCT05394740 | Gastric Adenoca... Gastroesophagea... Esophageal Aden... | Regorafenib Nivolumab CapeOX FOLFOX regimen | 20 Years - | National Cancer Center Hospital East | |
| Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | NCT00625651 | Metastatic Colo... Colon Cancer Colorectal Canc... Rectal Cancer | Placebo AMG 655 Modified FOLFOX... Bevacizumab | 18 Years - | Amgen | |
| Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma | NCT02195180 | Pancreatic Aden... | ERY001 Gemcitabine 5-fluoro-uracil... | 18 Years - | ERYtech Pharma | |
| Phase 2 Study of DKN-01 in Colorectal Cancer | NCT05480306 | Colorectal Canc... Colorectal Aden... Colo-rectal Can... Colorectal Canc... | DKN-01 FOLFIRI Bevacizumab FOLFOX | 18 Years - | Leap Therapeutics, Inc. | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC) | NCT01748851 | Gastric Carcino... | XELOX FOLFOX | 20 Years - | Dong-A University Hospital | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | NCT03597581 | Gastrointestina... Gastrointestina... Colorectal Canc... Colorectal Neop... Colorectal Carc... Gastric Cancer Gastric Neoplas... KRAS Mutation-R... CRC Colorectal Canc... | ompenaclid FOLFIRI Bevacizumab FOLFOX regimen | 18 Years - | Inspirna, Inc. | |
| A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer | NCT04621370 | Rectal Cancer Rectal Adenocar... Rectal Neoplasm... | Durvalumab FOLFOX Short Course Ra... Long course che... Capecitabine | 18 Years - | Cancer Research UK, Glasgow | |
| Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 | NCT03618758 | Gastric Cancer ... Peritoneal Carc... Intraperitoneal... mFOLFOX6 | Paclitaxel mFOLFOX6 regime... | 20 Years - 79 Years | Seoul National University Bundang Hospital | |
| Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC | NCT03202758 | Colorectal Canc... | Durvalumab, Tre... | 18 Years - | Centre Georges Francois Leclerc | |
| Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone | NCT00890305 | Metastatic Colo... | CT-011 FOLFOX | 18 Years - | Medivation, Inc. | |
| mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line | NCT03464968 | Biliary Cancer ... | Oxaliplatin,5FU... irinotecan,5FU,... | 20 Years - | Seoul National University Bundang Hospital | |
| MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | NCT04808323 | Rectal Adenocar... | Capecitabine Initial Dose of... Cohort A: Dose ... Cohort B: Dose ... Cohort C: Dose ... FOLFOX | 18 Years - | Medical College of Wisconsin | |
| Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone | NCT00890305 | Metastatic Colo... | CT-011 FOLFOX | 18 Years - | Medivation, Inc. | |
| Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More | NCT06293625 | Colon Cancer | Folfox Surgery | 70 Years - | Centre Hospitalier Universitaire Dijon | |
| A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX | NCT00494221 | Metastatic Colo... | AZD2171 FOLFOX (5-fluor... Placebo Cediran... | 18 Years - | AstraZeneca | |
| PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer | NCT05644249 | Gastric Cancer Peritoneal Carc... | Combined Doxoru... | 18 Years - | Vilnius University | |
| Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer | NCT00116506 | Colorectal Canc... Neoplasm Metast... | erlotinib FOLFOX bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer | NCT00807911 | Rectal Cancer | Adjuvant FL Adjuvant FOLFOX | 18 Years - | Asan Medical Center | |
| BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer | NCT03838406 | BRCA Gene Rearr... | BRCA 1 Chemotherapy | 19 Years - | Chung-Ang University | |
| A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis | NCT01269229 | Rectal Cancer | folfox short course Ra... | 18 Years - | Yonsei University | |
| Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma | NCT02195180 | Pancreatic Aden... | ERY001 Gemcitabine 5-fluoro-uracil... | 18 Years - | ERYtech Pharma | |
| The Inland Northwest Colon Cancer Survivor's Study | NCT01775254 | Colon Cancer | 18 Years - | Washington State University | ||
| Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More | NCT06293625 | Colon Cancer | Folfox Surgery | 70 Years - | Centre Hospitalier Universitaire Dijon | |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | NCT00819780 | Colon Cancer Colorectal Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab mFOLFOX6 | 18 Years - | Amgen | |
| Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | NCT04945720 | Hepatocellular ... | Hepatic artery ... Durvalumab | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer | NCT01274962 | Operable T2-3N+... | FOLFOX high dose rate ... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | NCT02128425 | Metastatic Colo... | FOLFOXIRI FOLFOX | 18 Years - 75 Years | Sun Yat-sen University | |
| FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX | NCT04167007 | Pancreatic Aden... | Gemcitabine FOLFOX | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach | NCT01611857 | Malignant Solid... Gastroesophagea... | Tivantinib FOLFOX | 18 Years - | SCRI Development Innovations, LLC | |
| Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer | NCT02849106 | Colorectal Canc... | biopsy to obtai... | 18 Years - | Institut Curie | |
| A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer | NCT01274962 | Operable T2-3N+... | FOLFOX high dose rate ... | 18 Years - | Sir Mortimer B. Davis - Jewish General Hospital | |
| Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI | NCT00934882 | Colorectal Neop... | Regorafenib (BA... | 18 Years - | Bayer | |
| Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | NCT00613080 | Colorectal Canc... | capecitabine oxaliplatin resection radiation thera... FOLFOX | 18 Years - | Radiation Therapy Oncology Group | |
| Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma | NCT02502370 | Small Bowel Ade... Adjuvant Chemot... | observation alo... LV5FU2 FOLFOX | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | NCT01047293 | Colorectal Canc... | RAD001 FOLFOX Bevacizumab | - | University of Utah | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | NCT05733689 | Gastroesophagea... | ctDNA Blood Tes... FLOT FOLFOX FOLFIRI FOLFIRINOX PACLITAXEL with... DOCETAXEL and I... NIVOLUMAB (alon... PEMBROLIZUMAB (... | 18 Years - | University of California, Irvine | |
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | NCT04991948 | Unresectable Me... | CYAD-101 FOLFOX Pembrolizumab | 18 Years - | Celyad Oncology SA | |
| Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer | NCT00443573 | Colon Cancer | recombinant nem... | 18 Years - 75 Years | ARCA Biopharma, Inc. | |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors | NCT00502567 | Advanced Solid ... | AZD2171 FOLFOX Pemetrexed Irinotecan (adm... Docetaxel | 18 Years - | AstraZeneca | |
| NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma | NCT02486601 | Cancer of Stoma... | nab-paclitaxel FOLFOX | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | NCT03692429 | Unresectable Me... | CYAD-101 FOLFOX FOLFIRI | 18 Years - | Celyad Oncology SA | |
| Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy | NCT04526886 | Colorectal Canc... Gastric Cancer Esophageal Canc... Ampullary Cance... Small Bowel Can... Appendix Cancer | Algorithm for c... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | NCT03662659 | Gastric Cancer Cancer of the S... Esophagogastric... | BMS-986213 Nivolumab XELOX FOLFOX SOX | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors | NCT00502567 | Advanced Solid ... | AZD2171 FOLFOX Pemetrexed Irinotecan (adm... Docetaxel | 18 Years - | AstraZeneca | |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | NCT05702229 | Gastric Cancer | Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine | 18 Years - | AstraZeneca | |
| FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer | NCT02128425 | Metastatic Colo... | FOLFOXIRI FOLFOX | 18 Years - 75 Years | Sun Yat-sen University | |
| Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer | NCT00786006 | Metastatic Panc... | FOLFIRI.3 FOLFOX | 18 Years - | Asan Medical Center | |
| Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | NCT03117972 | Metastatic Colo... | FOLFOXIRI FOLFOX FOLFIRI Bevacizumab LV5FU2 Capecitabine | 18 Years - 76 Years | Centre Hospitalier Universitaire de Besancon | |
| Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | NCT00778830 | Metastatic Colo... | Cetuximab FOLFIRI FOLFOX | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Study of Picoplatin in Colorectal Cancer | NCT00478946 | Colorectal Canc... | (FOLPI) Picopla... FOLPI FOLFOX | 18 Years - | Poniard Pharmaceuticals | |
| Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer. | NCT01248299 | Squamous Cell C... | FU-CDDP LV5FU2-CDDP FOLFOX TPF Best Supportive... | 18 Years - | Centre Oscar Lambret | |
| Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases | NCT01646554 | Colorectal Canc... Liver Metastase... KRAS Mutated Co... | Modified FOLFOX... Aflibercept Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
